CD274 and renal cell carcinoma: As a potential new anticancer strategy, the checkpoint inhibitors anti-PD-1 and anti-PD-L1 have attracted an enormous amount of interest and generated an encouraging clinical outcome in the treatment of patients with solid tumors, particularly in NSCLC, renal cell carcinoma and melanoma [20, 21].